nimotuzumab biomab egfr biocon theracim cimym biosciences canada theraloc oncoscience europe cimaher center molecular immunology havana cuba humanized monoclonal antibody orphan status us eu glioma marketing approval india china countries squamous cell carcinomas head neck undergoing several clinical trials like cetuximab nimotuzumab binds epidermal growth factor receptor egfr signalling protein normally controls cell division cancers receptor altered cause uncontrolled cell division hallmark cancer monoclonal antibodies block egfr stop uncontrolled cell division humanized humanmouse heavy chain humanized humanmouse nimotuzumab binds optimal affinity high specificity extracellular region egfr epidermal growth factor receptor results blockade ligand binding receptor activation epidermal growth factor receptor egfr key target development cancer therapeutics egfrtargeting drugs shown improve response used conventional treatments radiation therapy developed center molecular immunology cim havana cims commercialization arm cimab sa formed joint venture ym biosciences called cimym biosciences owned ym owned cimym biosciences licensed european rights nimotuzumab oncoscience ag south korean rights kuhnil pharmaceutical co ltd licensed japanese rights daiichi sankyo rights certain countries asia africa innogene kalbiotech pte licensees nimotuzumab include biocon biopharmaceuticals ltd bbpl india biotech pharmaceutical co ltd china delta laboratories colombia european chemicals sac quality pharma peru eurofarma laboratorios ltda brazil ferozsons labs pakistan laboratorio elea sacifya argentina el kendi pharmaceutical algeria laboratorios pisa mexicocitation needed december cimym biosciences dissolved sold assets related nimotuzumab innokeys pte according review nimotuzumab approved following squamous cell carcinoma head neck scchn india cuba argentina colombia ivory coast gabon ukraine peru sri lanka expired glioma pediatric adult cuba argentina philippines ukraine nasopharyngeal cancer china granted orphan drug status glioma usa glioma pancreatic cancer nimotuzumab additional phase ii clinical april daiichi sankyo announced halting multicenter randomized doubleblind placebocontrolled phase iii study investigating nimotuzumab firstline therapy patients unresectable locally advanced squamous cell lung cancer due safety issues certain patients received combination cisplatin vinorelbine radiotherapy toxicity safety nimotuzumab assessed several preclinical clinical studies wherein noticed side effects usually caused egfr inhibitors especially rashes skin toxicities negligible scientists hypothesized nimotuzumab binds cells express moderate high egfr nimotuzumab found well tolerated clinical trials common adverse reactions seen patients treated nimotuzumab httpsenwikipediaorgwikinimotuzumab